• Transition of CEO role

    Posted on 15 May 2013

    The Board of Photonz Corporation is delighted to announce the appointment of Dr James Campbell to the role of CEO as part of a staged transition that sees Dr Greg Collier assume the CEO role of the ASX-listed biotech company Invion Limited. 

  • Photonz's Chief Scientific Officer Wins NZBIO Award

    Posted on 20 March 2013

    Dr Hywel Griffiths, Chief Scientific Officer for Photonz Corp. was named the 2013 Young Biotechnologist of the Year by NZBIO at an award ceremony Tuesday evening.


  • Seeking commercial partners

    Posted on 9 November 2012

    AUCKLAND via ALGAE WORLD ASIA CONFERENCE SINGAPORE – 8 November 2012 – Talks are underway involving potential partners of Photonz Corporation as the company is finalising its process for manufacturing eicosapentaenoic acid (EPA) by fermentation of micro-algae.


Dr. Douglas Wilson appointed to Board of Directors

Posted on Aug. 13, 2010

Dr John Douglas Wilson ( MB, ChB, PhD, FRACP, FRCPA) has been appointed to the Board of Directors. His appointment adds to the Board considerable skill and experience from the pharmaceutical sector ahead of the Series B capital raising round.

Dr Wilson was Senior Vice President for Medical and Regulatory Affairs for Boehringer Ingelheim Pharmaceuticals (USA) for ten years where he oversaw a team of 400, including a number of medical staff, and was responsible for over 50 parallel drug developments. Subsequently, head of Boehringer's worldwide medical research group overseeing all research programmes and working on upward of 100 drugs, he later relocated to Ingelheim (Germany) as head of Medicine and Regulatory Affairs worldwide.

Dr Wilson is also Executive Chairman of ASX-listed biotech Phylogica (a drug discovery company) and is a director of Sea Dragon (a New Zealand company producing omega-3 oils by molecular distillation of fish oil).